Using a magnet-assisted subtraction technique, 17 complementary DNA (eDNA) clones were isOlatedthat were expressed in the normal lung but were decreased or lost In the corresponding tumor tissue of a non small cell lung carcinoma patlent@The luck of expression of six magnet assisted subtraction technique eDNA clones in three additional non-small cell lung cardnoma cases indicates their possible relevance for non-small cell lung carcinoma. Two eDNA clones revealed homology to genes ape cifically expressed in lung, @e., pulmonary surfactant-associated protein B and the receptor for advanced glycosylation end products of proteins. Three cDNA clones showed identity to eDNA sequences encoding cal modulin-like protein, glutamine synthetase, and cytoskeletal 13-actln.One cDNA clone is identical to a recently described human expressed sequence tag whose gene is still unknown.
INTRODUCTION
The majority of lung tumors can be divided histologically into four cell types. Squamous cell (or epidermoid), adeno-, and large cell carcinoma are summarized under the term of NSCLC. 3 In contrast, small cell carcinoma, the fourth type, consists of small, atypical cells containing neuro-secretory granuli. Histologically, different cell types and differentiation stages often appear within a malignant lung tumor and therefore contribute to tumor heterogeneity and combined tumor forms.
The causes of tumor formation are genetic mutational events that lead either to the overexpression of growth-promoting oncogenes or the inactivation of cell cycle-controlling tumor suppressor genes. Oncogenes like ras, myc, myb (1), raft (2) , or kit (3), and tumor suppressor genes such as the retinoblastoma gene (4â€"8)and the p53 gene (9â€"11)have been described in lung tumors. However, â€oehot spotâ€• regions of allelic deletions on different chromosomes suggest the involvement of additional, still unknown genes in NSCLC. It was shown that there are three distinct regions on 3p frequently deleted in lung cancer (12) . The gene for the receptor protein-tyrosine phospha tase--y has been implicated as a possible candidate tumor suppressor gene at 3p2l (13) . Loss of heterozygosity on chromosomes 8p (14) , 9p (15) , and lip, mainly at llpl3 (16) , is a common phenomenon in NSCLC. In addition, recent cytogenetic analysis of primary NSCLC tumors showed clonal abnormalities on all of the remaining chromosomes (17) .
Both overexpression and loss of expression of genes in NSCLC are important steps in the tumorgenesis of this type of cancer. The products of genes down-regulated in NSCLC most likely operate within a highly structured and integrated growth regulatory network. Their â€oefunctionaldeletionâ€• is thus an obligatory step in tumor predisposition, formation, and progression. Using MAST, we have identified cDNAs derived from genes which have been inactivated during NSCLC development.
MATERIALS AND METHODS
Normal and Tumor Lung Tissue. Normal and corresponding tumor lung tissues from four patients were put into liquid nitrogen immediately after resection to avoid RNA degradation. Total RNA was extracted from pulverized normal/tumor tissue according to the methods of Chomczynski and Sacchi (18) .
MAST. This technique has been described in detail by Schraml et aL (19) . For MAST, the normal and NSCLC tissue RNA (NjF@) was prepared from patient 1. For single-stranded tumor driver cDNA synthesis, mRNA was captured from 2.16 mg total tumor RNA by 18 mg Dynabeads Oligo(dT),@. cDNA synthesis,purification, andcalculationof the drivercDNA amountwas carried out as described (19) . Double-stranded normal tracer cDNA was synthesized from 10 @g bead-purified normal lung polyadenylated mRNA. cDNA blunt-ends were produced by a â€oefill-inâ€• reaction with 14 DNA poly merase, and the amount of cDNA was estimated by spectrophotometry. Sub traction hybridization was performed at 68Â°Cfor 3 days in a 0.5-mi Eppendorf tube containing 200 @d 0.75 Msodium chloride, 25 mM [N-(2-hydroxyethyl) piperazine-N'-(2-ethanesulfonic acid), pH 7.5J, 5 mM EDTA, 0.1% sodium dodecyl sulfate, 800 ng denatured, blunt-ended normal tracer cDNA, and 10
ILg tumor driver cDNA bound to Dynabeads. Ligation, blue/white colony screening, minipreparation, and vector-polymerase chain reaction of nonsub tracted, renatured, double-stranded, blunt-ended normal cDNA was performed according to the MAST protocol (19 were done accordingto the Sequenasepmtocol (USB).
RESULTS
Seventy-two cDNA clones were isolated by MAST. Of particular interest were those cDNA clones that showed no expression in the tumor tissue RNA of patient 1. Consequently, each of the clones varying between 37 and 338 base pairs in length was analyzed by Northern blot hybridization using total RNA from normal (Ni) and tumor tissue (Ti) of that patient. As can be seen in Table 1 
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Human fibronectinV00662 K0079988%/60 97%/i23â€" With the exception of 13 clones that were equally expressed in normal and tumor tissue, all MAST clones were sequenced. The cDNA sequences were compared to sequences in the Genbank/EMBL data base. Patient 1 developed a mixed squamous adenocarcinoma without lymph node involvement. To determine whether the lack of expres sion of the 17 MAST clones was restricted to the tumor of patient 1, we analyzed total normal/tumor RNA from three additional NSCLC patients. Two patients suffered from squamous cell carcinomas, and the third patient developed an adenocarcinoma. In contrast to the tumor of patient 1, these three cases presented advanced tumor stages with regional lymph node metastases. In Fig. 1 , six cDNA clones are represented that are differentially expressed in these four different NSCLC cases. In addition to clone 57 that derives from the SP-B gene, clone 18 also seems to be specifically expressed in lung tissue. As shown in Fig. 2 , the expected i.4-kilobase RAGE transcript could only be observed in lung tissue. Three clones (clones 37, 38, and 69) shared similarity to cytoplasmic f3-actin, calmodulin, and glutamine synthetase. Clone 9 binds to a 3.0-kilobase transcript in normal lung tissue and is homologous to a recently described human expressed sequence tag whose gene is still unknown (22) . Fig. 3 shows the comparison of the clone 9 and cDNA clone 1B936 3'-end sequences.
DISCUSSION
Using MAST, we identified six genes that were either not expressed or very weakly expressed in four histologically different primary NSCLCS, which suggests their relevance in the development of NSCLC. Five cDNA clones are derived from genes whose products act in diverse cellular processes including, Ca2@-dependent reactions (calmodulin-like protein), cytoskeletal organization (@-actin), metab olism (glutamine synthetase), homeostasis in lung (SP-B), and cell surface interactions (RAGE).
Both SP-B and RAGE are specifically expressed in the lung. By virtue of their lung specificity, a loss of expression of these genes could contribute to NSCLC formation and/or progression. Little is known about SP-B. It is expressed in type II pneumocytes and in the nonciliated columnal cells (Clara cells) in terminal bronchioles (23) . It is involved in the regulation of the recycling of surfactant and surfactant homeostasis. Since SP-B is produced only in these well differentiated cell types, the gene of SP-B might be down-regulated in tumorigenic cells originating from these cell types. Hormones such as glucocorticoid have positive effects on SP-B synthesis (24) . if this protein is involved in cellular differentiation and growth inhibitory mechanisms, hormonal treatment of Clara cell or type II pneumocyte derived NSCLCS may be promising. In addition, as shown for stir factant-associated protein A (25), SP-B might also be used as a diagnostic and differentiation marker for NSCLC.
Human RAGE and its full-length cDNA were characterized and isolated by Neeper et a!. (26) . RAGE belongs to the immunoglobulin superfamily ofcell surface molecules and shares significant homology with MUC18, NCAM, and CD2O. The protein is expressed on endo thelial cells and mononuclear phagocytes (27) , and it functions as a cell surface receptor for nonenzymatically glycosylated proteins. In addition to AGES that promote neovascularization in vivo (28) cell proliferation in vitro (26) . These observations suggest the involve ment of RAGE in endothelial cell growth and neovascularization effects in the lung. if RAGE acts as a putative endothelial growth factor receptor or even as an angiogenic factor, why is the RAGE gene suppressed in four NSCLCS? A possible explanation is that RAGE may not only mediate the binding and uptake of AGES, but it also degrades these molecules, as hypothesized by Neeper et a!. (26) . If RAGE is able to reduce the amount of neovascularization-promoting AGES, it may behave as a growth inhibitor or antiangiogenic factor that must be down-regulated to allow the growth of lung tumors. Further analysis of RAGE using in vitro models of angiogenesis and RAGE-expressing cell lines could provide evidence for its antiangio genic and thereby its antitumor growth effects.
In addition to the lung-specific proteins SP-B and RAGE, three other MAST cDNA clones showed homology to ubiquitously cx pressed proteins, i.e., calmodulin, cytoskeletal @3-actin, and glutamine synthetase. Although there is no direct evidence for tumor suppression by these proteins in vivo, some aspects are noteworthy.
It was demonstrated that genes coding for Ca2@-binding proteins were not expressed mammary tumors. Yaswen et a!. (29) described NB-i, a CLP gene, that was down-regulated in benzopyrene and k-ras-transformed human mammary epithelial cells. Interestingly, the CL, gene product acted as a putative tumor suppressor in that it was able to significantly increase the duration ofthe cell cycle, specifically at G1/S and the G1/Gs boundary, in CLP-transfected human breast epitheial cells (30) . An additional calcium-binding protein gene be longing to the S100 family was found to be expressed in normal epithelial mammary cells but not in the tumor-derived human mam mary epithelial cells (31) . The fact that CaM or CaM-related protein genes are not expressed in different tumor types suggests a broader role in the suppression of tumor growth.
Tumor cells often show loss of cytoskeletal protein organization, which contributes to tumor cell invasiveness (32). Gene and protein expression of cytoskeletal proteins are tightly regulated during cell Clone9 differentiation and development. In parallel to @3-actin, whose gene is not expressed in four NSCLCS, the keratin 5 gene was shown to be expressed in normal cultured mammary epithelial cells but was absent in tumor-derived cell lines (33) . Interestingly, Rastinejad et al. (34, 35) even achieved a dramatic decrease of tumorgenicity of a non differentiating mutant myogenic cell line, NMU2, by constitutive expression of 3'-untranslated RNAs encoding cytoskeletal proteins. A decrease of expression of genes that encode cytoskeletal proteins is thus correlated with loss of tumor suppression.
Consequences of the ability to circumvent internal and external growth controls are accelerated cell proliferation and an increased demand for energy. Glutamine, for instance, is a precursor for the synthesis of purines, pyrimidines, and proteins but is also one of the major substrates for tumor energy metabolism. Glutamine synthetase catalyzes the formation of glutamine from glutamate using ammo nium ions and AlT. It was shown that, in rapidly growing hepatoma cells, the activity of glutamine synthetase was decreased (36) . The paradox that glutamine synthetase activity is decreased in tumor cells and that large amounts of glutamine are required for tumor cell growth has not yet been resolved. It would be interesting to investigate whether a forced reactivation of glutamine synthetase has growth suppressive effects on cultivated tumor cells.
We assume that the down-regulation of the six described genes whose products are active in cytoskeletal organization, Ca2@-regula tion, control of angiogenesis, cellular metabolism, and surfactant homeostasis are â€oedownstreameffectsâ€• of mutational events that occurred during NSCLC development.
As hypothesized by Liotta (37) , an advanced tumor has acquired a series of specific genetic and regulatory changes that permitted the transition through tumor initiation (loss of cell cycle control), forma tion (uncontrolled proliferation and change of cell shape), and pro gression (invasion, angiogenesis, and metastasis). A subtractive hy bridization with normal lung cDNA and an excess of tumor cDNA from an NSCLC patient should enrich those cDNA clones whose opment. Furthermore, the lack of expression of these six cDNA clones was independent of cellular heterogeneity, independent of tumor type, and independent of tumor stage. However, the examination of addi tional NSCLC cases should provide further evidence for the involve ment of these genes in NSCLC. Although the inactivation of these genes is more likely a result rather than a cause of NSCLC, the possible tumor-suppressive effects of their products should not be excluded. Tumor-suppressed genes that encode CLP (30), a-tropomyosin (35) , or maspin (38) are also able to suppress tumorgenicity of tumor cell lines. Although their genes are tumor suppressed and therefore not classical tumor suppres sor genes, their products behave like tumor suppressors. Transfection assays in tumorgenic cell lines with full-length cDNAs of these six MAST clones should permit us to evaluate their tumor-suppressive ability.
